Bicara Therapeutics’ $108 Million Series B Financing

Goodwin Procter advised Bicara Therapeutics on the deal.Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program BCA101…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now